Keyword: Johnson & Johnson
Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.
Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.
Amgen’s Kyprolis is finally on track for blockbuster status this year, and new data in tandem with J&J's Darzalex could help boost it even further.
Johnson & Johnson has been battling talc claims for years, and Wednesday the company suffered its latest loss.
Purdue’s pending opioid settlement could rank as the largest deal ever inked. Where do the industry’s other major settlements fall on that list?
J&J enlisted British celebrity home stylist Laurence Llewelyn-Bowen to raise awareness of blood cancer and its symptoms this month.
Johnson & Johnson has faced payer pushback for its controversial antidepressive Spravato. Could new data in high-risk patients help its cause?
With scrutiny stateside mounting on the opioid industry, makers of the controversial drugs are looking to India as a new market.
After Endo and Allergan inked county deals last week, drugmakers are lining up to reach global settlements in thousands of opioid lawsuits.
Purdue Pharma has reportedly offered up to $12 billion as part of a settlement to resolve thousands of opioid lawsuits.
